USANA Health Sciences earnings missed by $0.54, revenue fell short of estimates
USANA Health Sciences (USNA) reported Q3 EPS of -$0.11, missing estimates by $0.54, with revenue at $206M vs. $219.02M expected. FY 2026 guidance: EPS $0.55 (vs. $0.76 estimate), revenue $900M (vs. $909M). Stock down 27.59% YTD. InvestingPro rates financial health as 'fair performance.'
How this was made
The 30-second read
Why it matters
The earnings shortfall and guidance cut may trigger short‑term sell pressure, but longer‑term fundamentals remain to be evaluated.
Market read
The earnings miss is the primary catalyst for USNA's near‑term price action.
What to watch
Potential cost‑saving initiatives or upcoming product launches not discussed in the release.
Background
USANA Health Sciences is a nutrition‑supplement company listed on NYSE. The report covers its Q3 2026 earnings and FY guidance.
Ticker impact
Q3 earnings missed estimates and FY2026 guidance was lowered, indicating weaker performance.
likely pressure as the market prices in the earnings miss and lower FY guidance
Both EPS and revenue fell short of consensus and FY2026 EPS guidance was cut from $0.76 to $0.55.
Market effects
Health‑supplement sector may see modest pullback as a mid‑cap peer reports weaker demand.
US‑based consumer‑health stocks could face short‑term pressure.
Limited; impact confined to USNA and its niche market.
Counterpoint
If the miss is viewed as a temporary setback, the stock could be a buying opportunity at lower levels.
Key entities
- companyUSANA Health Sciences
Issuer of the earnings report.
